On this page
This entry or formulation may be investigational and may not correspond to an FDA-approved product; safety and efficacy may not have been established. Kairo lists it for identification and record-keeping only.
Overview
Product & regulatory status
The studies summarized here do not establish routine cognitive enhancement or a substitute for standard stroke treatment.
What the evidence shows
Small placebo-controlled trial
A study in 62 stroke patients reported improvements with Cortexin added to basic treatment. Its small size and limited reporting restrict confidence in broad claims about neurological recovery. [1]
Larger published study
A multicenter study in 272 patients compared treatment sequences with placebo. The accessible abstract reports favorable results but gives limited numerical outcome and adverse-event detail; the conclusion is stronger than what can be independently assessed from the abstract alone. [2]
What remains unknown
Independent replication, transparent patient-important outcome estimates, and applicability outside the studied stroke populations remain gaps.
Safety
Limited safety detail
The reports describe clinical monitoring in stroke patients. They do not establish long-term safety for healthy people or safety equivalence to other animal-derived or peptide-containing preparations. [2]
Preparation-specific evidence
A product’s mixture and manufacturing characteristics matter. A catalog name cannot confirm that a supplied product matches the material used in a clinical trial. [1]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [3]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [4]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Is Cortexin interchangeable with Cerebrolysin?
No. They are different preparations studied in different trials. Evidence for one cannot establish efficacy or dosing for the other.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- Cortexin: small acute stroke trial2008 · Original research · PubMed
- Cortexin: placebo-controlled ischemic stroke study2014 · Original research · PubMed
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.